• Cyber adAPT

  Led · Series A · May 2016

  Cyber adAPT is a Half Moon Bay, Calif.-based security company led by President & CEO Kirsten Bay that provides an attack detection platform. Its platform monitors 100% of traffic inside mobile-enabled enterprise networks to surface hidden malicious threats that bypass perimeter defenses. The company has been deployed with government and commercial-sector customers over the last year. Cyber adAPT recently closed an additional $6.0M in Series A funding and, per the article, has raised $15.0M in Series A to date. The company plans to use the proceeds to expand into core markets. Reuben Richards of Black River Investments will join the board as Chairman in conjunction with the investment. Cyber adAPT is a real-time, network-based threat detection platform that exposes sophisticated adversaries hiding inside enterprise networks. The system collects and stores metadata to establish host behavior baselines, growing the system’s intelligence over time. It alerts on likely malicious attacks already present or newly created inside the perimeter and provides a dashboard for rapid threat assessment and reporting capabilities. The product provides visibility around critical business assets and exposes blind spots within the enterprise. The platform can be integrated with NBA systems and/or SIEMs. Founded in 2014 and led by president and CEO Kirsten Bay, the company is based in Half Moon Bay, California.

• PhageTech

  Led · Series A · Sep 2015

  PhageTech, Inc. is a development-stage medical diagnostics company based in Irvine, CA that is building biosensors that use a bacteriophage substrate to detect analytes in urine, blood, and other body fluids. The core product, the PhageTech Biosensor™, was originally developed at the University of California, Irvine with NIH grant support. When paired with a portable reader, the sensor aims to deliver near-patient test results in under one minute, giving physicians real-time data for earlier diagnosis and improved treatment outcomes. The technology targets early detection of cancers as well as a broad range of other diseases. Current efforts are focused on completing product development and securing FDA clearance. Richard Henson serves as CEO, and the company remains pre-commercial with no disclosed revenue or user metrics. The recent capital infusion will fund final engineering, regulatory submissions, and preparation for market entry.

No current team members are available.